|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
18
|
|
pubmed:dateCreated |
2009-11-3
|
|
pubmed:abstractText |
Interferon beta (IFNbeta) administered subcutaneously is immunogenic in some patients with multiple sclerosis (MS) and leads to the development of neutralizing antibodies (NAbs). Considerable evidence has accumulated that NAbs diminish or abolish IFNbeta bioactivity, but there is less evidence that NAbs impact clinical efficacy of the drug.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1526-632X
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
3
|
|
pubmed:volume |
73
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1485-92
|
|
pubmed:meshHeading |
pubmed-meshheading:19884576-Adult,
pubmed-meshheading:19884576-Antibodies,
pubmed-meshheading:19884576-Contrast Media,
pubmed-meshheading:19884576-Drug Tolerance,
pubmed-meshheading:19884576-Female,
pubmed-meshheading:19884576-Gadolinium,
pubmed-meshheading:19884576-Humans,
pubmed-meshheading:19884576-Immunologic Factors,
pubmed-meshheading:19884576-Interferon-beta,
pubmed-meshheading:19884576-Magnetic Resonance Imaging,
pubmed-meshheading:19884576-Male,
pubmed-meshheading:19884576-Middle Aged,
pubmed-meshheading:19884576-Multiple Sclerosis,
pubmed-meshheading:19884576-Prospective Studies,
pubmed-meshheading:19884576-Single-Blind Method,
pubmed-meshheading:19884576-Time Factors,
pubmed-meshheading:19884576-Treatment Outcome
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study.
|
|
pubmed:affiliation |
UMDNJ-New Jersey Medical School, 185 South Orange Ave., MSBH506, Newark, NJ 07103, USA. pachner@umdnj.edu
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
